Six-year clinical and MRI quantitative susceptibility mapping (QSM) follow-up in neurological Wilson’s disease under zinc therapy: a case report
To the Editor,
Wilson’s disease (WD) is an inherited disorder of copper metabolism, resulting in pathological accumulation of copper, principally in the liver, brain and cornea. The causative gene is ATP7B (13q14.3) that encodes a copper-transporting P-type ATPase. Liver or neuropsychiatric involvement is a hallmark of the disease . Copper chelators or zinc salts are commonly given as therapy, although there is no international consensus on first-line therapy. Improvement in T2-signal alterations in follow-up brain MRI have been documented in WD patients undergoing zinc treatment (zinc sulfate) . Recent studies have shown that copper deposit may result in a measurable difference in quantitative susceptibility mapping (QSM) at brain MRI of neurological and non-neurological WD patients compared to healthy controls at field strength of 7T , as well as in young patients with neurological WD even before T1 or T2 brain signal alteration at 1.5T . Herein, we report a significant...
We wish to thank Dr. Yi Wang (Ph.D.), Dr. Pascal Spincemaille (Ph.D.), and colleagues from the Department of Radiology, Weill Cornell Medical College (New York, USA), for developing the MEDI_toolbox and for their valuable help and suggestions.
Compliance with ethical standards
Patient consent was obtained. Details have been removed from this case report to ensure anonymity.
Conflict of interest
The authors declare that they have no conflicts of interest.
- 1.Bandmann O., Weiss KH, Kaler SG. (2015) Wilson’s disease and other neurological copper disorders. Lancet Neurol;14(1): 103–113. https:// doi: https://doi.org/10.1016/S1474-4422(14)70190-5
- 4.Doganay S, Gumus K, Koc G, Bayram AK, Dogan MS, Arslan D, Gumus H, Gorkem SB, Ciraci S, Serin HI, Coskun A (2018) Magnetic susceptibility changes in the basal ganglia and brain stem of patients with Wilson’s disease: evaluation with quantitative susceptibility mapping. Magn Reson Med Sci 17(1):73–79. https://doi. https://doi.org/10.2463/mrms.mp.2016-0145
- 5.Czlonkowska A, Litwin T, Karliński M, Dziezyc K, Chabik G, Czerska M (2014) Dpenicillamine versus zinc sulphate as first-line therapy for Wilson’s disease. Eur J Neurol 4:599–606. https://doi. https://doi.org/10.1111/ene.12348